Tính đối xứng trong bệnh Parkinson: nghiên cứu hình ảnh PET 11C-PE2I

Riederer P, Jellinger KA, Kolber P, Hipp G, Sian-Hülsmann J, Krüger R (2018) Lateralisation in Parkinson disease. Cell Tissue Res 373(1):297–312. https://doi.org/10.1007/s00441-018-2832-z Poewe W, Mahlknecht P (2012) Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease. Expert Rev Neurother 12(8):911–914. https://doi.org/10.1586/ern.12.75 Yust-Katz S, Tesler D, Treves TA, Melamed E, Djaldetti R (2008) Handedness as a predictor of side of onset of Parkinson's disease. Parkinsonism Relat Disord 14(8):633–635. https://doi.org/10.1016/j.parkreldis.2008.01.017 Barrett MJ, Wylie SA, Harrison MB, Wooten GF (2011) Handedness and motor symptom asymmetry in Parkinson's disease. J Neurol Neurosurg Psychiatry 82(10):1122–1124. https://doi.org/10.1136/jnnp.2010.209783 Shi J, Liu J, Qu Q (2014) Handedness and dominant side of symptoms in Parkinson's disease. Med Clin 142(4):141–144. https://doi.org/10.1016/j.medcli.2012.11.028 Wiberg A, Ng M, Al Omran Y, Alfaro-Almagro F, McCarthy P, Marchini J, Bennett DL, Smith S, Douaud G, Furniss D (2019) Handedness, language areas and neuropsychiatric diseases: insights from brain imaging and genetics. Brain. https://doi.org/10.1093/brain/awz257 Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, Lee CS, McKenzie J, McCormick S, Samii A, Troiano A, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Calne DB, Stoessl AJ (2009) Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 132(11):2970–2979. https://doi.org/10.1093/brain/awp209%JBrain Yagi S, Yoshikawa E, Futatsubashi M, Yokokura M, Yoshihara Y, Torizuka T, Ouchi Y (2010) Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET. J Nucl Med 51(8):1250–1257. https://doi.org/10.2967/jnumed.110.076802 Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K (2018) Longitudinal change of clinical and biological measures in early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. Mov Disord 33(5):771–782. https://doi.org/10.1002/mds.27361 Miller-Patterson C, Buesa R, McLaughlin N, Jones R, Akbar U, Friedman JH (2018) Motor asymmetry over time in Parkinson’s disease. J Neurol Sci 393:14–17. https://doi.org/10.1016/j.jns.2018.08.001 Lee CS, Schulzer M, Mak E, Hammerstad JP, Calne S, Calne DB (1995) Patterns of asymmetry do not change over the course of idiopathic Parkinsonism. Neurology 45(3):435. https://doi.org/10.1212/WNL.45.3.435 Li W, Lao-Kaim NP, Roussakis AA, Martin-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P (2018) (11) C-PE2I and (18) F-Dopa PET for assessing progression rate in Parkinson's: a longitudinal study. Mov Disord 33(1):117–127. https://doi.org/10.1002/mds.27183 Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170. https://doi.org/10.1002/mds.22340 Simuni T, Siderowf A, Lasch S, Coffey CS, Caspell-Garcia C, Jennings D, Tanner CM, Trojanowski JQ, Shaw LM, Seibyl J, Schuff N, Singleton A, Kieburtz K, Toga AW, Mollenhauer B, Galasko D, Chahine LM, Weintraub D, Foroud T, Tosun D, Poston K, Arnedo V, Frasier M, Sherer T, Chowdhury S, Marek K, Initiative* tPsPM (2018) Longitudinal change of clinical and biological measures in early Parkinson's Disease: Parkinson's progression markers initiative cohort. Mov Disord: Official J Mov Disord Soc 33(5):771–782. https://doi.org/10.1002/mds.27361 Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184. https://doi.org/10.1136/jnnp.55.3.181 Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25(15):2649–2653. https://doi.org/10.1002/mds.23429 Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, Giladi N, Holloway RG, Moore CG, Wenning GK, Yahr MD, Seidl L (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19(9):1020–1028. https://doi.org/10.1002/mds.20213 Plotnik M, Giladi N, Balash Y, Peretz C, Hausdorff JM (2005) Is freezing of gait in Parkinson's disease related to asymmetric motor function? Ann Neurol 57(5):656–663. https://doi.org/10.1002/ana.20452 Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM (2012) FSL NeuroImage 62(2):782–790. https://doi.org/10.1016/j.neuroimage.2011.09.015 Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, Farde L, Sedvall G (1999) Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I. NeuroImage 9(1):108–116 Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, Lundkvist C, Olsson H, Guilloteau D, Emond P, Farde L (2003) [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 30(9):1220–1230. https://doi.org/10.1007/s00259-003-1212-3 Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L (2006) Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging 33(6):657–668. https://doi.org/10.1007/s00259-005-0027-9 Li W, Lao-Kaim NP, Roussakis AA, Martín-Bastida A, Valle-Guzman N, Paul G, Loane C, Widner H, Politis M, Foltynie T, Barker RA, Piccini P (2018) 11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson's: a longitudinal study. Mov Disord: Official J Mov Disor Soc 33(1):117–127. https://doi.org/10.1002/mds.27183 Brooks DJ (2010) Imaging dopamine transporters in Parkinson's disease. Biomark Med 4(5):651–660. https://doi.org/10.2217/bmm.10.86 Sossi V, Dinelle K, Jivan S, Fischer K, Holden JE, Doudet D (2012) In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET. J Nucl Med 53(5):813–822. https://doi.org/10.2967/jnumed.111.101436 Marinus J, van Hilten JJ (2015) The significance of motor (a)symmetry in Parkinson's disease. Mov Disord 30(3):379–385. https://doi.org/10.1002/mds.26107 Uitti RJ, Baba Y, Whaley NR, Wszolek ZK, Putzke JD (2005) Parkinson disease: Handedness predicts asymmetry. Neurology 64(11):1925–1930. https://doi.org/10.1212/01.WNL.0000163993.82388.C8 Reinoso G, Allen JC Jr, Au W-L, Seah S-H, Tay K-Y, Tan LCS (2015) Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur J Neurol 22(3):457–463. https://doi.org/10.1111/ene.12476 Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE (2007) Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22(16):2409–2417. https://doi.org/10.1002/mds.21743 López IC, Ruiz PJ, Del Pozo SV, Bernardos VS (2010) Motor complications in Parkinson's disease: ten year follow-up study. Mov Disord 25(16):2735–2739. https://doi.org/10.1002/mds.23219 Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J, McCormick S, Ruth TJ, Sossi V, de la Fuente-Fernandez R, Stoessl AJ (2011) Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 134(Pt 11):3290–3298. https://doi.org/10.1093/brain/awr233 Tedroff J, Ekesbo A, Rydin E, Långström B, Hagberg G (1999) Regulation of dopaminergic activity in early Parkinson's disease. Ann Neurol 46(3):359–365. https://doi.org/10.1002/1531-8249(199909)46:3<359:Aid-ana11>3.0.Co;2-g Oaks AW, Marsh-Armstrong N, Jones JM, Credle JJ, Sidhu A (2013) Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. PLoS ONE 8(8):e70872. https://doi.org/10.1371/journal.pone.0070872 Nikolaus S, Antke C, Hautzel H, Mueller HW (2016) Pharmacological treatment with L-DOPA may reduce striatal dopamine transporter binding in in vivo imaging studies. Nuklearmedizin Nucl Med 55(1):21–28. https://doi.org/10.3413/Nukmed-0764-15-08 Kuramoto L, Cragg J, Nandhagopal R, Mak E, Sossi V, de la Fuente-Fernández R, Stoessl AJ, Schulzer M (2013) The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling. PLoS ONE 8(10):e76595. https://doi.org/10.1371/journal.pone.0076595 van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis RB (2002) Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 10(1):36–43